For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250925:nRSY8757Aa&default-theme=true
RNS Number : 8757A Eco Animal Health Group PLC 25 September 2025
25 September 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Result of Annual General Meeting
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that at its Annual General Meeting
held today all resolutions proposed to the meeting were duly passed.
Votes received in relation to each resolution were as follows:
Resolution For Against
% Discretionary % %
01 35,042,909 99.900 Nil 0.00 34,924 0.100
02 34,840,996 99.330 Nil 0.00 234,879 0.670
03 28,794,146 82.091 Nil 0.00 6,281,729 17.909
04 28,807,698 82.126 Nil 0.00 6,269,884 17.874
05 34,854,006 99.363 Nil 0.00 223,576 0.637
06 34,828,949 99.291 Nil 0.00 248,633 0.709
07 34,854,513 99.364 Nil 0.00 223,069 0.636
08 34,854,513 99.364 Nil 0.00 223,069 0.636
09 35,026,916 99.860 Nil 0.00 48,959 0.140
10 35,029,648 99.869 Nil 0.00 45,976 0.131
11 35,024,511 99.854 Nil 0.00 51,364 0.146
12 35,014,864 99.826 Nil 0.00 61,011 0.174
13 35,014,269 99.824 Nil 0.00 61,606 0.176
-Ends-
Contacts
020 8447 8899
ECO Animal Health Group plc
David Hallas (Chief Executive Officer)
Christopher Wilks (Chief Financial Officer)
ICR Healthcare (Financial PR) 020 3709 5700
Mary-Jane Elliott
Jessica Hodgson
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Philip Davies
Sam Butcher
Panmure Liberum (Joint Broker) 020 3100 2000
Emma Earl
Will Goode
Mark Rogers
Rupert Dearden
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com/)
( )
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGSELFLIEISEFU